BioSpace News Archive

Elucida Oncology, Inc., is a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy with its first-in-class, ultra-small nanoparticle C’Dot drug conjugate (CDC) platform.

AltruBio is developing first-in-class immune-modulators targeting diseases of #immunology and #inflammation. Its world-class global team brings a breadth of expertise in immunology and drug development that will help advance their biologic treatments to patients.

Developing next generation technologies for precision medicine and drug discovery.

Cirius Therapeutics is a clinical-stage pharmaceutical company developing innovative therapies for diseases caused by insulin resistance including Type 2 Diabetes, the metabolic consequences of Obesity, and MASLD/MASH

A commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines for high unmet medical needs.

We develop clinically driven, first-in-class, tissue-specific therapeutics from human diseased tissue to treat specific fibrotic disease populations.

The Prelude Network (Prelude), the fastest-growing network of fertility clinics and largest provider of comprehensive fertility services in the U.S., is the clinic network of Inception - a company whose mission is to shift the paradigm of the fertility market by raising the standard of care, streamlining fragmented components into an integrated system and enhancing the overall patient experience.

Apostle Inc. is a biotechnology company focusing on cell-free DNA technologies used in a liquid biopsy - a developing technology that can have clinical applications in early cancer detection, cancer monitoring, non-invasive prenatal tests and many other potentials.

DMD Therapeutics Inc. is a privately held corporation registered in Delaware. The Company was founded by Carlo Rago, PhD and Ron Berenson, MD in 2016 to develop novel therapeutics for DMD and other muscular dystrophies.

Rhythm is a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare MC4R pathway diseases. The company is leveraging the Rhythm Engine -- comprised of its TEMPO Registry, GO-ID genotyping study and Uncovering Rare Obesity program -- to improve the understanding, diagnosis and potentially the treatment of these disorders.